Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

IO102-IO103

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

IO Biotech

Drug class:

PD-L1 inhibitor, IDO inhibitor

Related drugs:

‹

Dual TDO/IDO Inhibitor (0)

IDO/TDO dual inhibitor (0)

atezolizumab (236)

durvalumab (198)

sugemalimab (7)

envafolimab (6)

atezolizumab/hyaluronidase (1)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

Dual TDO/IDO Inhibitor (0)

IDO/TDO dual inhibitor (0)

›

LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3
PD-L1 negative	Melanoma	PD-L1 negative	Melanoma	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3
PD-L1 expression	Head and Neck Cancer	PD-L1 expression	Head and Neck Cancer	pembrolizumab + IO102-IO103 Sensitive: C3 – Early Trials pembrolizumab + IO102-IO103 Sensitive : C3	pembrolizumab + IO102-IO103 Sensitive: C3 – Early Trials pembrolizumab + IO102-IO103 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + IO102-IO103 Sensitive: C3 – Early Trials pembrolizumab + IO102-IO103 Sensitive : C3	pembrolizumab + IO102-IO103 Sensitive: C3 – Early Trials pembrolizumab + IO102-IO103 Sensitive : C3